Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European, and APAC companies seeking partnerships, acquisitions, novel technologies, and funding in China. ChinaBio® has also organized over 30 conferences in China focused on investment and partnering, including the ChinaBio® Partnering Forum which draws nearly 1000 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today: a widely read newsletter covering the China life science industry. He also serves on the board of a medical device and cancer drug company, and formerly the BayHelix Group, a group of (mostly) Chinese life science executives. Headquartered in Shanghai, ChinaBio® has staff in San Diego, Palo Alto, and Basel, Switzerland. Greg lives and works in Shanghai and visits California a few times a year to enjoy the blue skies and sandy beaches.

Dr. Jeffry Wu is a Partner at Panacea Venture, a science-focused venture capital firm focusing on investing in and incubating early-stage life science companies with disruptive and breakthrough technologies and discoveries that can potentially address huge unmet medical needs and enhance quality of life.

Previously, Jeffry worked for Johnson & Johnson’s corporate venture and private equity funds in the United States and China and dedicated to life science investments.  He graduated from University of Science & Technology of China and holds a PhD degree in Neurobiology from College of Physicians & Surgeons at Columbia University and an MBA degree from INSEAD. He has been a CFA charterholder since 2007.

Josie Zhou has extensive experience serving global and local biopharmaceutical clients across a broad range of topics in China, with a focus on R&D ,launch, growth strategy, commercial model innovation and organization.
Josie has authored articles on China healthcare innovation and most recently the COVID-19 impact on the China biopharma, and she has been one of co-authors on the yearly McKinsey China healthcare insights in partnership with Biocentury on “Bridge to innovation” series since 2017.